Answers are grounded in this paper and cite their sources.
Screening for disease before the arrival of symptoms is an intuitive cornerstone of preventive medicine and good clinical practice in many cases. However, screening is not appropriate for all conditions. Disease, test, and treatment should all be considered when developing a rational approach to screening.1–4 Specifically, screening may be warranted if the target disease has significant morbidity and mortality. Testing in specific populations should be able to detect early disease, have relatively low risk, and a low rate of pseudo-disease detection (including both false positive results and true disease which naturally regresses). Lastly, treatments should be more effective if employed early.56 This article reviews the available literature addressing these key aspects of screening for pulmonary arterial hypertension (PAH).
No takes yet. Share an insight, caveat, or question.
Leary et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: